COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine are available for routine office visits. More Information-PLEASE CLICK HERE
Gregory S. Sibley, MD
“I place a high premium on customer service, and that starts with me. I insist that patients are seen on time, and that wait times for consultations and treatment start times are as short as possible. We are dealing with cancer, after all. At VCS we have the best of both worlds (private practice with close personal attention and also academic with cutting edge research and treatment options).”
Dr. Gregory S. Sibley joined Virginia Cancer Specialists after 14 years in Radiation Oncology at Sibley Memorial Hospital in Washington, D.C. Throughout his career, Dr. Sibley has focused on providing the highest quality care in the field of radiation oncology. He has positioned himself as an expert in the multi-disciplinary treatment of cancer and in state-of-the-art radiation treatment planning techniques. Within the US Oncology Network, Dr. Sibley is a member of the Executive Committee for Radiation Oncology and Vice-Chair for the Technology Committee. Dr. Sibley has authored over 20 peer-reviewed publications, many while on faculty at Duke University Medical Center. Although well-versed in the treatment of multiple cancers, Dr. Sibley has special interest in breast cancer, brachytherapy for prostate cancer, and intensity-modulated radiotherapy for head and neck, and lung cancers.
In his spare time, Dr. Sibley is an avid hockey player and triathlete.
Carboplatin/Paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiotherapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium
Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy